Fully human IgG2 mAb binding PCSK9. Same mechanism as alirocumab. FOURIER trial 2017 established CV event reduction. Glagov trial showed atherosclerosis regression on IVUS.
Half-Life (t½)
SC: 336h
Dosing Guidelines
SC: Typical 140 mg (Range: 140–140 mg)
Target Organ Systems
cardiovascular
Interactions
Alirocumab (synergistic): Same PCSK9 target, different mAb. Do not co-administer.